Security Name | Ticker | % of Net Assets |
---|---|---|
ABBVIE INC | ABBV | 7.10% |
AMGEN INC. | AMGN | 5.48% |
MODERNA INC | MRNA | 4.51% |
VERTEX PHARMACEUTICALS | VRTX | 4.22% |
GILEAD SCIENCES, INC. | GILD | 4.14% |
REGENERON PHARMACEUTICALS | REGN | 4.01% |
CORTEVA INC | CTVA | 3.18% |
ALNYLAM PHARMACEUTICALS | ALNY | 3.10% |
ILLUMINA INC | ILMN | 2.98% |
BIOGEN IDEC, INC. | BIIB | 2.78% |
SEAGEN INC | SGEN | 2.77% |
ASTRAZENECA PLC ADR | AZN | 2.52% |
ROYALTY PHARMA PLC- CL A | RPRX | 2.48% |
BIOMARIN PHARMACEUTICAL | BMRN | 2.17% |
SAREPTA THERAPEU | SRPT | 1.92% |
INCYTE CORP | INCY | 1.87% |
BIO-TECHNE CORP | TECH | 1.87% |
BIONTECH SE-ADR | BNTX | 1.73% |
VIATRIS INC | VTRS | 1.66% |
HORIZON THERAPEUTICS PLC | HZNP | 1.66% |
NEUROCRINE BIOSCIENCES IN | NBIX | 1.58% |
ICON PLC | ICLR | 1.49% |
EXACT SCIENCES | EXAS | 1.45% |
BIOHAVEN PHARMAC | BHVN | 1.44% |
UNITED THERAPEUTICS CORP | UTHR | 1.44% |
APELLIS PHARMACE | APLS | 1.43% |
BEAM THERAPEUTICS INC | BEAM | 1.35% |
IONIS PHARMACEUTICALS, IN | IONS | 1.34% |
DENALI THERAPEUT | DNLI | 1.32% |
NATERA INC | NTRA | 1.32% |
ARROWHEAD PHARMACEUTICALS | ARWR | 1.29% |
SYNEOS HEALTH, INC. | SYNH | 1.27% |
GUARDANT HEALTH INC | GH | 1.26% |
MEDPACE HOLDINGS | MEDP | 1.25% |
MIRATI THERAPEUT | MRTX | 1.25% |
CHEMOCENTRYX INC | CCXI | 1.24% |
INTELLIA THERAPE | NTLA | 1.24% |
JAZZ PHARMACEUTICALS PLC | JAZZ | 1.22% |
EXELIXIS, INC. | EXEL | 1.18% |
HALOZYME THERAPEUTICS INC | HALO | 1.13% |
BLUEPRINT MEDICI | BPMC | 1.12% |
CRISPR THERAPEUTICS AG | CRSP | 1.10% |
FATE THERAPEUTIC | FATE | 1.00% |
BIOCRYST PHARM | BCRX | 0.97% |
ULTRAGENYX PHARM | RARE | 0.85% |
NOVAVAX INC | NVAX | 0.85% |
IOVANCE BIOTHERAPEUTICS | IOVA | 0.75% |
VERACYTE INC | VCYT | 0.74% |
NEOGENOMICS INC | NEO | 0.70% |
EDITAS MEDICINE | EDIT | 0.67% |
IRONWOOD PHARMAC | IRWD | 0.63% |
EMERGENT BIOSOLUTIONS INC | EBS | 0.59% |
CAREDX INC | CDNA | 0.57% |
CASSAVA SCIENCES INC | SAVA | 0.34% |
Other (Cash, derivatives and other liabilities) | 0.48% | |
Total: |
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Partners Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Fund Management (Europe) Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Partners India Management.
© 2022 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.